A5064305763- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- CNS Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Blood groups and transfusion
- Chronic Myeloid Leukemia Treatments
- Parathyroid Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Neuroendocrine Tumor Research Advances
- Cardiovascular Function and Risk Factors
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Cardiomyopathy and Myosin Studies
- Acute Lymphoblastic Leukemia research
- Cardiac Imaging and Diagnostics
- Erythrocyte Function and Pathophysiology
- Viral-associated cancers and disorders
- Renal Diseases and Glomerulopathies
- Cardiac pacing and defibrillation studies
- Brain Metastases and Treatment
- Cardiovascular Effects of Exercise
- Platelet Disorders and Treatments
- Protein Kinase Regulation and GTPase Signaling
- Pancreatitis Pathology and Treatment
University College Hospital
2019-2025
University College London
2019-2025
Royal London Hospital
2022-2025
The Royal Free Hospital
2024-2025
University College London Hospitals NHS Foundation Trust
2019-2024
Royal Brompton Hospital
2011-2018
St Helier Hospital
2017
East Kent Hospitals University NHS Foundation Trust
2015
Imperial College London
2013-2014
Ealing Hospital
2013
<h3>Importance</h3>Risk stratification of patients with nonischemic dilated cardiomyopathy is primarily based on left ventricular ejection fraction (LVEF). Superior prognostic factors may improve patient selection for implantable cardioverter-defibrillators (ICDs) and other management decisions.<h3>Objective</h3>To determine whether myocardial fibrosis (detected by late gadolinium enhancement cardiovascular magnetic resonance [LGE-CMR] imaging) an independent incremental predictor mortality...
Cardiovascular magnetic resonance is the gold-standard technique for assessment of ventricular function. Although left volumes and ejection fraction are strong predictors outcome in dilated cardiomyopathy (DCM), there limited data regarding prognostic significance right (RV) systolic dysfunction (RVSD). We investigated whether cardiovascular RV function has value DCM.We prospectively studied 250 consecutive DCM patients with use resonance. RVSD, defined by fraction≤45%, was present 86 (34%)...
<h3>Objective</h3> Myocardial fibrosis identified by late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM) is associated adverse events, but its value as an independent risk factor for sudden cardiac death (SCD) unknown. We investigated the role of LGE-CMR stratification HCM. <h3>Methods</h3> conducted a prospective cohort study tertiary referral centre. Consecutive HCM (n=711, median age 56.3 years, IQR 46.7–66.6; 70.0%...
Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopoietic stem-cell transplantation (HSCT) secondary
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there no consensus on optimal treatment. Daratumumab, monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 also expressed activated T cells, daratumumab may act via immunomodulatory effects. We evaluated the efficacy safety monotherapy in an international retrospective study...
Background: Myocardial fibrosis, identified by late gadolinium enhancement cardiovascular magnetic resonance, predicts outcomes in chronic heart failure (HF). Its prognostic significance new-onset HF and reduced left ventricular ejection fraction (LVEF) is unclear. We investigated whether the pattern extent of fibrosis predict survival LVEF initially uncertain pathogenesis. Methods Results: Of 120 consecutive patients with (<6 months) LVEF, 31 (26%) had infarct 25 (21%) midwall 64 (53%)...
Abstract High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there limited evidence to guide whether intercalate HD-MTX (i-HD-MTX) between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone given 21-day intervals) or give it the end treatment (EOT) R-CHOP-21. We conducted a retrospective, multicenter analysis 334 DLBCL who...
Not available.
Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra-cellular deposition of light-chain aggregates in critical organs. An immunomodulatory agent-based quadruplet including anti-CD38 therapy has not been investigated as a first-line treatment AL amyloidosis. We report the UK experience daratumumab-bortezomib-thalidomide-dexamethasone for Consecutive patients with new diagnosis systemic between 2021 and 2023 were retrospectively reviewed from National Amyloidosis...
Summary Monoclonal immunoglobulin M‐associated type I cryoglobulinaemia is poorly characterised. We screened 534 patients with monoclonal IgM disorders over a 9‐year period and identified 134 cryoglobulins. Of these, 76% had Waldenström macroglobulinaemia (WM), 5% other non‐Hodgkin lymphoma (NHL) 19% gammopathy of undetermined significance (MGUS). Clinically relevant IgM‐associated (including cold agglutinin disease [CAD], anti‐MAG antibodies, amyloidosis Schnitzler syndrome) coexisted in...
Summary Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, BCMA‐directed drug–antibody conjugate, relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one were reviewed, with median three prior lines therapy. The follow‐up was 12 months (95% CI 4–19), and five doses delivered. best haematological overall response rate...